Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES, FUWAI HOSPITAL · Oct 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a condition called heart failure with preserved ejection fraction (HFpEF), which is a type of heart failure where the heart pumps normally but still has problems. The goal of the study is to better understand how to recognize and diagnose HFpEF early, using advanced imaging techniques like MRI, nuclear medicine imaging, and echocardiography. The researchers want to gather more information about the heart's structure and function in patients with HFpEF, especially since many people with this condition don’t show clear symptoms until it's more advanced.

To be eligible for the study, participants must have certain heart-related measurements, like a left ventricular ejection fraction (a measure of heart pumping ability) of 50% or more, and specific levels of certain proteins in the blood that indicate heart strain. They also need to have symptoms of heart failure and at least one abnormality in heart structure or function. Participants can expect to undergo various imaging tests and provide health information that will help researchers gain insights into HFpEF. The study is currently recruiting participants of all genders, and it’s important to note that certain heart conditions or severe issues may exclude someone from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • left ventricular ejection fraction (LVEF)≥50%；
• • N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml;
• • symptoms and syndromes of heart failure;
• • At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler).
• Exclusion Criteria:
• • Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc.
• • Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ;
• • Severe arrhythmia;
• • Severe primary cardiac valvular disease;
• • Restrictive pericardial disease;
• • Refuse to participate in the study.